Global Liver Cirrhosis Market to Exhibit 4.36% CAGR 2016-2020

Published Date : May 30, 2016

Albany, NY, May 30, 2016: Market intelligence aggregator,, has announced the addition of a new market study on the global liver cirrhosis market. The report studies the market for the treatments for liver cirrhosis and pipeline candidates. The expected trajectory of the liver cirrhosis market from 2016 to 2020 is elaborated upon in the report. The report is titled ‘Global Liver Cirrhosis Market 2016-2020’ and is available for sale on the official website of 

The medical background of liver cirrhosis is explained in the report to brief the readers about the crucial facts about the disease. Liver cirrhosis leads to a progressive shutdown of the liver’s functions due to irreversible scarring. This can be caused by sustained exposure to strong viral infections as well as heavy and sustained intake of strong toxins such as alcohol. Nonalcoholic steatohepatitis can also cause liver cirrhosis.

According to the report, the global liver cirrhosis market is expected to exhibit a steady 4.36% CAGR from 2016 to 2020. The rising prevalence of liver cirrhosis, attributable to the increasing abuse of alcohol, is the prime driver responsible for expansion of the global liver cirrhosis market. The prevalence of liver cirrhosis is also helped by the lack of strict patient adherence to the prescribed treatment regimen.

On the plus side, advancement in medical technology in recent decades has also made liver cirrhosis treatment more efficient and effective. This has boosted patient confidence in the regimen, driving the demand for the same. The high volume of unmet medical needs in developing regions has also given the global liver cirrhosis market a promising opportunity to exploit in the coming years.

For Sample Copy, click here:

The impact that various driving and restraining factors are expected to have on the growth trajectory of the global liver cirrhosis market in the coming years is described in the report both quantitatively and qualitatively. 

Segmentation of the global liver cirrhosis market is performed on the basis of treatment type, molecule type, and geography. The medicines required to treat liver cirrhosis itself and the medicines required to treat complications of liver cirrhosis are quite distinct and comprise the two treatment segments of the global liver cirrhosis market. Biologics and small molecules are the two major types of molecules used to treat liver cirrhosis. Geographically, the report looks into the performance of the liver cirrhosis market in the Americas, APAC, and EMEA (Europe, the Middle East, and Africa), describing each regional segment in great detail.

In terms of competitive reports of the market, the report profiles major players such as GlaxoSmithKline, Johnson & Johnson, F. Hoffman-La Roche, Merck, and Gilead Sciences. The comprehensive information about the market performance of these and other major players provided in the report will help readers understand and apply the competitive dynamics of the market to their advantage.

To order report Call Toll Free: 866-997-4948 or send an email on